VERO - Venus Concept Inc Stock Price, Fair Value and News

0.62USD-0.01 (-1.59%)Delayed

Market Summary

USD0.62-0.01

Delayed

-1.59%

VERO Stock Price

View Fullscreen

VERO RSI Chart

VERO Valuation

Market Cap

3.9M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

0.05

EV/EBITDA

-2.56

Price/Free Cashflow

-0.4

VERO Price/Sales (Trailing)

VERO Profitability

Operating Margin

57.91%

EBT Margin

-51.14%

Return on Equity

126.44%

Return on Assets

-32.57%

Free Cashflow Yield

-251.76%

VERO Fundamentals

VERO Revenue

Revenue (TTM)

73.3M

Rev. Growth (Yr)

-14.87%

Rev. Growth (Qtr)

-3.6%

VERO Earnings

Earnings (TTM)

-27.7M

Earnings Growth (Yr)

100.05%

Earnings Growth (Qtr)

100.04%

Breaking Down VERO Revenue

Last 7 days

-8.8%

Last 30 days

-19.5%

Last 90 days

-44.6%

Trailing 12 Months

-73.6%

How does VERO drawdown profile look like?

VERO Financial Health

Current Ratio

2.06

Debt/Equity

-3.31

Debt/Cashflow

-0.14

VERO Investor Care

Shares Dilution (1Y)

16.51%

Diluted EPS (TTM)

-6.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	73.3M	0	0	0
2023	93.6M	86.4M	82.5M	76.4M
2022	109.4M	110.9M	107.8M	99.5M
2021	86.1M	94.9M	98.8M	105.6M
2020	100.3M	89.5M	84.0M	78.0M
2019	41.5M	63.9M	85.2M	110.4M
2018	20.8M	20.5M	21.2M	22.0M
2017	17.9M	20.1M	20.6M	21.3M
2016	16.8M	16.4M	16.0M	15.6M
2015	0	0	0	17.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Venus Concept Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 11, 2023	mandarello michael	acquired	-	-	834	general counsel & secretary
Aug 11, 2023	mandarello michael	sold (taxes)	-	-	-233	general counsel & secretary
Mar 25, 2023	georgiadis anna	sold (taxes)	-	-	-5,873	chief hr officer
Mar 25, 2023	mandarello michael	acquired	-	-	18,750	general counsel & secretary
Mar 25, 2023	mcgrail william h	acquired	-	-	12,500	sr. vp
Mar 25, 2023	mcgrail william h	sold (taxes)	-	-	-4,717	sr. vp
Mar 25, 2023	georgiadis anna	acquired	-	-	18,750	chief hr officer
Mar 25, 2023	della penna domenic	sold (taxes)	-	-	-12,778	exec vp & general manager
Mar 25, 2023	della penna domenic	acquired	-	-	37,500	exec vp & general manager
Mar 25, 2023	mandarello michael	sold (taxes)	-	-	-5,409	general counsel & secretary

Which funds bought or sold VERO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-3.91	-132	170	-%
May 15, 2024	Essex Woodlands Management, Inc.	sold off	-100	-1,285,240	-	-%
May 15, 2024	Essex Woodlands Management, Inc.	new	-	752,634	752,634	0.22%
May 15, 2024	Tower Research Capital LLC (TRC)	added	40.62	-1,038	4,844	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	25,403	25,403	-%
May 15, 2024	MASTERS CAPITAL MANAGEMENT LLC	unchanged	-	-163,001	230,335	0.01%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-9,899	14,587	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	-13.00	18.00	-%
May 10, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-196	277	-%

Are Funds Buying or Selling VERO?

Are funds buying VERO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VERO

No. of Funds

Unveiling Venus Concept Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 07, 2024	madryn asset management, lp	17.8%	1,353,428	SC 13D/A
Mar 01, 2024	intracoastal capital, llc	4.99%	320,765	SC 13G
Feb 29, 2024	masters capital management llc	7.44%	0	SC 13D/A
Feb 28, 2024	ew healthcare partners, l.p.	45.5%	4,431,947	SC 13D/A
Feb 22, 2024	madryn asset management, lp	20.0%	1,353,428	SC 13D/A
Jan 22, 2024	ew healthcare partners, l.p.	49.7%	4,431,947	SC 13D/A
Oct 23, 2023	ew healthcare partners, l.p.	43%	3,377,321	SC 13D/A
Oct 12, 2023	madryn asset management, lp	39.7%	3,561,242	SC 13D/A
Sep 15, 2023	ew healthcare partners, l.p.	43%	3,377,321	SC 13D/A
Jul 14, 2023	ew healthcare partners, l.p.	49.5%	4,322,090	SC 13D/A

Recent SEC filings of Venus Concept Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 07, 2024	SC 13D/A	13D - Major Acquisition
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 25, 2024	EFFECT	EFFECT
Apr 24, 2024	8-K	Current Report
Apr 17, 2024	EFFECT	EFFECT
Apr 17, 2024	8-K	Current Report
Apr 16, 2024	UPLOAD	UPLOAD

Peers (Alternatives to Venus Concept Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Venus Concept Inc News

Latest updates

Venus Concept Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-3.6%	17,479,000	18,132,000	17,616,000	20,075,000	20,531,000	24,286,000	21,539,000	27,266,000	26,406,000	32,634,000	24,563,000	25,828,000	22,597,000	25,830,000	20,680,000	16,996,000	14,508,000	31,854,000	26,154,000	27,818,000	24,580,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	7,257,000	7,111,000	7,363,000	9,119,000	7,177,000	5,099,000	5,228,000	12,108,000	7,386,000	7,744,000	6,515,000
Gross Profit	-3.4%	11,647,000	12,063,000	12,185,000	14,220,000	13,699,000	15,789,000	13,373,000	19,046,000	17,763,000	22,837,000	17,306,000	18,717,000	15,234,000	16,711,000	13,503,000	11,897,000	9,280,000	19,746,000	18,768,000	20,074,000	18,065,000
Operating Expenses	-1.5%	19,407,000	19,697,000	18,947,000	19,978,000	21,854,000	24,678,000	24,798,000	26,172,000	25,199,000	26,905,000	22,695,000	17,191,000	22,070,000	26,926,000	18,797,000	20,705,000	52,861,000	37,643,500	25,332,000	24,023,000	19,933,000
S&GA Expenses	-6.8%	7,374,000	7,912,000	6,907,000	8,380,000	8,032,000	9,300,000	9,369,000	10,523,000	11,084,000	13,564,000	9,810,000	11,253,000	8,906,000	7,390,000	5,657,000	4,545,000	8,611,000	12,426,000	9,201,000	10,250,000	9,532,000
R&D Expenses	6.9%	1,785,000	1,670,000	1,925,000	1,965,000	2,637,000	2,574,000	3,024,000	2,712,000	2,643,000	3,147,500	2,232,000	2,353,000	2,407,000	1,711,000	1,849,000	1,570,000	2,624,000	2,367,000	1,686,000	1,920,000	2,061,000
EBITDA Margin	-6.7%	-0.38	-0.36	-0.33	-0.38	-0.39	-0.37	-0.30	-0.23	-0.14	-0.14	-0.21	-0.22	-0.35	-0.90	-	-	-	-	-	-	-
Interest Expenses	-45.0%	1,187,000	2,160,000	1,539,000	1,487,000	1,443,000	1,317,500	1,153,000	969,000	858,000	415,500	940,000	930,000	1,731,000	1,534,000	1,750,000	2,220,000	2,108,000	1,610,500	1,979,000	2,022,000	1,555,000
Income Taxes	121.3%	37,000	-174,000	-321,000	189,000	235,000	-814,000	-162,000	-18,000	272,000	-1,316,000	616,000	-7,000	-	2,191,000	-966,000	-633,000	589,000	990,000	-80,000	61,000	886,000
Earnings Before Taxes	13.9%	-9,752,000	-11,324,000	-9,277,000	-7,132,000	-9,388,000	-10,754,000	-14,658,000	-10,530,000	-8,364,000	-5,426,000	-8,222,000	235,000	-9,435,000	-12,838,000	-8,287,000	-10,398,000	-50,114,000	-21,745,000	-9,057,000	-5,417,000	-4,219,000
EBT Margin	-5.2%	-0.51	-0.49	-0.44	-0.49	-0.48	-0.45	-0.36	-0.29	-0.20	-0.22	-0.31	-0.32	-0.48	-1.05	-	-	-	-	-	-	-
Net Income	100.0%	5,000	-11,233,000	-9,068,000	-7,409,000	-9,657,000	-9,986,500	-14,605,000	-10,559,000	-8,619,000	-9,423,000	-8,838,000	-135,000	-176,000	-14,301,000	-7,243,000	-9,588,000	-50,190,000	-20,927,500	-8,640,000	-5,910,000	-5,273,000
Net Income Margin	22.8%	-0.38	-0.49	-0.44	-0.48	-0.48	-0.44	-0.40	-0.34	-0.25	-0.18	-0.24	-0.23	-0.36	-1.04	-	-	-	-	-	-	-
Free Cashflow	-262.4%	-2,903,000	-801,000	-4,072,000	-2,144,000	-5,958,000	-3,446,000	-3,906,000	-7,383,000	-12,581,000	-719,000	-7,260,000	-4,031,000	-8,273,000	47,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.2%	85.00	94.00	99.00	106	113	125	121	133	144	157	138	147	149	161	147	151	155	191	21.00	23.00	30.00
Current Assets	-8.6%	61.00	66.00	72.00	76.00	78.00	84.00	81.00	89.00	98.00	110	95.00	103	107	115	100	100	100	100	19.00	22.00	28.00
Cash Equivalents	-5.7%	5.00	5.00	5.00	6.00	6.00	12.00	7.00	11.00	18.00	31.00	16.00	23.00	27.00	34.00	13.00	14.00	21.00	16.00	9.00	10.00	15.00
Inventory	-9.1%	21.00	23.00	23.00	23.00	23.00	24.00	24.00	22.00	21.00	21.00	21.00	20.00	18.00	18.00	19.00	19.00	19.00	19.00	6.00	6.00	5.00
Net PPE	-7.0%	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	5.00	1.00	1.00	1.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27.00	-	-	-
Liabilities	-0.1%	107	107	110	112	113	117	111	109	111	116	109	110	113	117	110	111	109	114	43.00	36.00	35.00
Current Liabilities	-5.5%	29.00	31.00	26.00	35.00	36.00	40.00	30.00	28.00	30.00	35.00	29.00	31.00	29.00	33.00	37.00	38.00	41.00	48.00	28.00	15.00	12.00
Long Term Debt	2.5%	73.00	71.00	79.00	71.00	70.00	70.00	78.00	78.00	77.00	77.00	77.00	76.00	76.00	75.00	67.00	65.00	63.00	61.00	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	2.00
LT Debt, Non Current	-100.0%	-	71.00	79.00	71.00	70.00	70.00	78.00	78.00	77.00	77.00	77.00	76.00	76.00	75.00	67.00	65.00	63.00	61.00	-	-	-
Shareholder's Equity	-62.9%	-21.91	-13.45	-	-	-0.21	8.00	10.00	23.00	33.00	42.00	29.00	37.00	36.00	44.00	37.00	40.00	47.00	77.00	19.00	27.00	32.00
Retained Earnings	-3.7%	-271	-261	-250	-241	-234	-224	-214	-199	-189	-180	-176	-166	-166	-157	-142	-135	-125	-75.69	-217	-208	-200
Additional Paid-In Capital	0.5%	249	248	239	235	233	232	224	222	222	221	204	204	203	202	69.00	69.00	171	150	69.00	69.00	68.00
Accumulated Depreciation	1.8%	6.00	6.00	5.00	5.00	5.00	6.00	12.00	12.00	11.00	11.00	11.00	11.00	10.00	10.00	10.00	9.00	9.00	9.00	-	-	-
Shares Outstanding	14.9%	6.00	6.00	6.00	6.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	-	-	-	-	-	-	-
Minority Interest	0.9%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-0.78	-0.65	-0.47	1.00	1.00	2.00	3.00	-	-	-
Float	-	-	-	-	7.00	-	-	-	18.00	-	-	-	107	-	-	-	50.00	-	-	-	26.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-271.8%	-2,878	-774	-4,075	-2,122	-5,888	-3,407	-3,860	-7,289	-12,424	-401	-7,192	-3,958	-8,220	130	-4,068	-9,307	-15,405	-13,728	-14,425	-2,907	-8,535
Share Based Compensation	-4.5%	339	355	364	369	481	552	551	558	443	466	536	558	508	535	547	539	517	1,105	-	-	375
Cashflow From Investing	7.4%	-25.00	-27.00	3.00	-22.00	-70.00	-39.00	-46.00	-94.00	-157	-318	-108	-73.00	-53.00	-2,273	-100	42.00	-61.00	11,624	-4,894	-101	-245
Cashflow From Financing	104.1%	2,594	1,271	2,876	1,852	803	8,238	143	12.00	-384	15,731	22.00	98.00	968	23,662	2,913	2,670	20,428	2,121	20,672	9,083	10,326

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VERO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Revenues	$ 17,479	$ 20,531
Cost of goods sold:
Cost of goods and services sold	5,832	6,832
Gross profit	11,647	13,699
Operating expenses:
Selling and marketing	7,374	8,032
General and administrative	10,248	11,185
Research and development	1,785	2,637
Total operating expenses	19,407	21,854
Loss from operations	(7,760)	(8,155)
Other expenses:
Foreign exchange (gain) loss	324	(352)
Finance expenses	1,668	1,508
Loss on disposal of subsidiaries	0	77
Loss before income taxes	(9,752)	(9,388)
Income tax expense	37	235
Net loss	(9,789)	(9,623)
Net loss attributable to stockholders of the Company	(9,794)	(9,657)
Net income attributable to non-controlling interest	$ 5	$ 34
Net loss per share:
Basic (in dollars per share)	$ (1.68)	$ (1.84)
Diluted (in dollars per share)	$ (1.68)	$ (1.84)
Weighted-average number of shares used in per share calculation:
Basic (in shares)	5,829	5,237
Diluted (in shares)	5,829	5,237
Leases [Member]
Revenue
Revenues	$ 3,593	$ 5,761
Cost of goods sold:
Cost of goods and services sold	1,477	1,747
Products and Services [Member]
Revenue
Revenues	13,886	14,770
Cost of goods sold:
Cost of goods and services sold	$ 4,355	$ 5,085

VERO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 5,087	$ 5,396
Accounts receivable, net of allowance of $5,317 and $7,415 as of March 31, 2024, and December 31, 2023, respectively	27,168	29,151
Inventories	20,978	23,072
Prepaid expenses	1,034	1,298
Advances to suppliers	4,926	5,604
Other current assets	1,508	1,925
Total current assets	60,701	66,446
LONG-TERM ASSETS:
Long-term trade receivables	9,906	11,318
Deferred tax assets	1,148	1,032
Severance pay funds	429	573
Property and equipment, net	1,229	1,322
Operating right-of-use assets, net	4,081	4,517
Intangible assets	7,582	8,446
Total long-term assets	24,375	27,208
TOTAL ASSETS	85,076	93,654
CURRENT LIABILITIES:
Trade payables	7,787	9,038
Accrued expenses and other current liabilities	12,133	12,437
Current portion of long-term debt	4,154	4,155
Income taxes payable	479	366
Unearned interest income	1,444	1,468
Warranty accrual	1,107	1,029
Deferred revenues	926	1,076
Operating lease liabilities	1,418	1,590
Total current liabilities	29,448	31,159
LONG-TERM LIABILITIES:
Long-term debt	72,552	70,790
Accrued severance pay	467	634
Deferred tax liabilities	11	15
Unearned interest revenue	724	671
Warranty accrual	268	334
Operating lease liabilities	2,846	3,162
Other long-term liabilities	672	338
Total long-term liabilities	77,540	75,944
TOTAL LIABILITIES	106,988	107,103
Commitments and Contingencies (Note 9)
STOCKHOLDERS’ EQUITY (DEFICIT) (Note 15):
Common Stock, $0.0001 par value: 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 6,355,230 and 5,529,149 issued and outstanding as of March 31, 2024, and December 31, 2023, respectively	30	30
Additional paid-in capital	249,180	247,854
Accumulated deficit	(271,697)	(261,903)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(22,487)	(14,019)
Non-controlling interests	575	570
Equity, Including Portion Attributable to Noncontrolling Interest	(21,912)	(13,449)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 85,076	$ 93,654

About Venus Concept Inc

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

CEO	Mr. Rajiv Kanishka Liyanaarchchie De Silva
WEBSITE	venusconcept.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	384

Venus Concept Inc Frequently Asked Questions

What is the ticker symbol for Venus Concept Inc? What does VERO stand for in stocks?

VERO is the stock ticker symbol of Venus Concept Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Venus Concept Inc (VERO)?

As of Fri May 17 2024, market cap of Venus Concept Inc is 3.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERO stock?

You can check VERO's fair value in chart for subscribers.

What is the fair value of VERO stock?

You can check VERO's fair value in chart for subscribers. The fair value of Venus Concept Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Venus Concept Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VERO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Venus Concept Inc a good stock to buy?

The fair value guage provides a quick view whether VERO is over valued or under valued. Whether Venus Concept Inc is cheap or expensive depends on the assumptions which impact Venus Concept Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERO.

What is Venus Concept Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VERO's PE ratio (Price to Earnings) is -0.14 and Price to Sales (PS) ratio is 0.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VERO PE ratio will change depending on the future growth rate expectations of investors.